1. Generics Bulletin
  2. >>Business

Goldman Ends Endo Coverage Following Q2 EBITDA Guide

NY-Based Investment Bank Halves Its 2023 Vasostrict Sales Guide

 
• By Dean Rudge

One of the largest investment banks in the US has cancelled its coverage of Endo after the US-based firm revealed the extent of generic competition to its lucrative Vasostrict brand.

Endo shares had been 'sent reeling' • Source: 360b/Shutterstock

Goldman Sachs is to cease coverage of struggling Endo International plc. The move follows the US-based firm guiding for its adjusted EBITDA to fall by as much as 65% quarter-over-quarter in the wake of generic competition to its $900m Vasostrict (vasopressin) injectable.

The New York-based investment bank typically publishes a report of Endo’s quarterly financial results and other material events. But it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Neuraxpharm Targets Asia-Pacific In Latest Phase Of Expansion Beyond Europe

 
• By Dean Rudge

Neuraxpharm has launched its Australian affiliate as part of its continued international expansion beyond Europe. The company will introduce CNS treatments including its acquired Nuvigil, Provigil, and the recently TGA-approved Briumvi for multiple sclerosis.

The Generics Bulletin Top 50, Part Two: Leading Players Leapfrog The Competition

 
• By Dave Wallace

In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 
• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

The Generics Bulletin Top 50, Part One: German Giants Rise Up The Ranks

 
• By Dave Wallace

Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.

More from Generics Bulletin